CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cellectis S.A.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026
$0.93−0.11 (-11.01%)
Close on Oct 19, 2026
- Market cap
- $93.15M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Cellectis has not reported a dividend
No dividend per share appears in Cellectis's annual filings since fiscal 2014.